Navigation Links
Lamotrigine is One of the Most Commonly Prescribed Drugs Among Newly Diagnosed Bipolar Disorder Patients in the United States

BURLINGTON, Mass., Oct. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through analysis of U.S. longitudinal patient-level claims data, antiepileptic drugs (AEDs), atypical antipsychotics and selective serotonin reuptake inhibitors capture the largest patient shares among all therapies assessed in newly diagnosed bipolar disorder patients across all three lines of therapy. Although no single agent from any of these drug classes was shown to dominate first-line treatment of newly diagnosed bipolar disorder patients, the AED lamotrigine (GlaxoSmithKline's Lamictal, generics) led other individual agents with nearly 20 percent of first-line patient share. According to thought leaders interviewed by Decision Resources, lamotrigine is considered to be beneficial for preventing and treating bipolar depression, one of the more challenging aspects of treating bipolar disorder.

The report Treatment Algorithms in Bipolar Disorder finds that among newly diagnosed patients, Abilify (Bristol-Myers Squibb/Otsuka) captured the highest first-line patient share within the atypical antipsychotic drug class, despite the availability of multiple generically available agents. Abilify's high patient share among agents in this class is likely due to relatively favorable reimbursement status, a more favorable tolerability profile than other atypical antipsychotics and approval to treat multiple psychiatric indications, which can contribute to physician awareness and preference.

The report also finds that, together, quetiapine products (AstraZeneca's Seroquel, generics and AstraZeneca's Seroquel XR) claimed the highest percentage of patient share within the atypical antipsychotic class among recently treated bipolar disorder patients. Combined, these agents earned over 12 percent patient share during the key therapy period analyzed. Bipolar disorder patients recently treated with Seroquel XR progress to the drug from quetiapine at a greater rate than those recently treated with quetiapine who progress from Seroquel XR. Seroquel XR is approved to treat multiple psychiatric indications, is dosed once daily and is generally subject to fewer market access hurdles than other branded atypical antipsychotics. These factors all contribute to recently treated patients' preferential progression from quetiapine to Seroquel XR.

"Our study findings indicate that quetiapine products are popular options for the treatment of bipolar disorder, and this aligns with the opinions of interviewed experts," said Decision Resources Senior Business Insights Analyst Alana Simorellis, Ph.D. "Quetiapine's efficacy in treating bipolar depression, an area of high unmet need in the bipolar disorder market, gives the molecule an advantage in physician prescribing over most other atypical antipsychotics. In addition, quetiapine and quetiapine XR are approved for all phases of bipolar disorder treatment and are viewed by thought leaders as efficacious options for insomnia and anxiety."

About Decision Resources
Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Though Over One-Third of Rheumatologists Have Prescribed Xeljanz for Their Rheumatoid Arthritis Patients, Physicians are Still Concerned With the Drugs Limited Post-Marketing Experience and Risks of Infection and Malignancy
2. House Bill Preserves Medicare Patient Access to Doctor-Prescribed Equipment Says AAHomecare
3. New Research: Nationwide Report Shows Prescribed Drugs Not Detected in More Than One-Third of Pain Patient Samples
4. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
5. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
6. Ophthalmic Drugs: World Market Prospects 2012-2022
7. Antithrombotic/Anticoagulant Drugs: World Market 2012-2022
8. INTAC™ Technology Combats Misuse of Extended Release Drugs
9. Contract Research Organizations Set to Experience Rapid Growth as Development Costs for New Drugs Continue to Rise
10. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
11. Bilcare and CSIR to Partner on nonClonableID Technology for Authentication of Drugs
Post Your Comments:
(Date:11/24/2015)... 24, 2015 . ... adds Latest Guidebook for Chinese Medical Device ... published in November 2015 to the medical devices ... library at . ... growing global economies with a fifth population in ...
(Date:11/24/2015)... , Nov. 24, 2015  Figure 1, a ... and share medical cases, has launched a new completely ... the web version allows radiologists, who work primarily on ... To further engage with its radiologist user base, Figure ... of North America (RSNA) Annual ...
(Date:11/24/2015)... 24, 2015 --> ... MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists ... grow at the fastest rates? This visiongain ... trends, opportunities and prospects there. ,  ,Our 199-page report ... lucrative areas in the industry and the future market ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Cancer patients, survivors, caregivers, family ... a live taping of the next CURE Connections® video series on ... 2015 Symposium at Georgetown University Hotel & Conference Center in Washington, D.C. , ...
(Date:11/24/2015)... ... ... American Family Care (AFC), the nation’s leading provider of urgent care and accessible ... Atlanta’s North Point Mall. The clinic is designed to test the concept of addressing ... operate through Dec. 24. , Holiday Pop-Up Clinic , Official Opening November 27, 6 ...
(Date:11/24/2015)... , ... November 24, 2015 , ... With Thanksgiving right ... is sharing safety tips to help protect your family and vehicle. , According to ... the 2013 Thanksgiving holiday weekend. Amica is sharing the following safety tips from the ...
(Date:11/24/2015)... Irvine, CA (PRWEB) , ... November 24, 2015 , ... Cold Shoulder , LLC ... Kickstarter last week and hit their goal of $20,000 in under 10 hours. ... aims to bring the new PRO Weight Loss Vest to the market. , The ...
(Date:11/24/2015)... PALMYRA, Wis (PRWEB) , ... November 24, 2015 ... ... Process scholarship award at Cleveland University-Kansas City (CU-KC), in Overland Park, ... scholarship from Chiropractor and University President Carl S. Cleveland III on October 16. ...
Breaking Medicine News(10 mins):